TandemAI raises $35M in Series A for small molecule discovery, wet labs
TandemAI, a small molecule- and preclinical-focused technology company, raised $35 million in a Series A round of financing a little over a year after raising an initial $25 million to get started.
CEO Jeff He says the company offers a three-in-one approach for biotech and pharma companies: a drug discovery platform of small molecules, China-based wet labs, and experts across various fields including chemistry and AI, all of whom work with clients to bring a drug candidate out of the preclinical stage.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.